Cymbalta (Duloxetine) Tapering Guide
Cymbalta (duloxetine) is an SNRI antidepressant used for depression, anxiety, and some pain conditions. It is widely prescribed as a first- or second-line option when an SNRI is chosen. This guide and medication taper calculator help you plan how to taper off Cymbalta safely with your prescriber.
Dosage
Duloxetine is supplied as enteric-coated bead capsules — typically 20 mg, 30 mg, and 60 mg (availability varies by region). Capsules must not be split, crushed, or chewed, or the enteric coating is lost. The smallest routine capsule strength is often 20 mg/day.
Steps below the lowest capsule usually need careful bead counting or a compounded liquid. Duloxetine has a high withdrawal risk and a short half-life, so gradual hyperbolic tapering is standard when you want to get off antidepressants.
Duloxetine taper schedule
Choose a common starting dose to preview an example hyperbolic schedule you can take to your prescriber — free, no email required. This example has 37 steps and takes about 144 weeks in total. It is a planning tool, not a dose instruction.
Starting dose
- Selected start
- 60 mg/day · 1× daily
- Taper speed
- Slow
- Region (formulations)
- US
- Modelled occupancy at start
- ~76.2%
Tablet/liquid products used for dosing tips — not your location. Example uses US formulary; change region in the custom builder.
Swipe sideways to see every column.
Rows highlighted: larger occupancy drop than target — consider smaller steps or longer holds. If symptoms are intolerable, return to the previous dose and talk to your prescriber.
Steps that cannot be made from whole or half licensed tablets point to the liquid / compounding note below — ask your prescriber before changing how you take your dose.
Want a copy to keep?
The full duloxetine schedule is already shown below. Enter your email to also receive a PDF and HTML copy you can save or share with your prescriber — optional, and we never gate the schedule behind it.
It's not a substitute for medical advice. This calculator can help you visualise a tapering schedule but before making any changes to your medication plan it's necessary to consult a medical professional. Ask a psychiatrist — available after you request your protocol.
Dose vs occupancy
This example is spread across 37 gradual steps. The curve below shows why the last few milligrams matter most: at low doses, small dose changes produce large drops in serotonin-transporter occupancy.
What this shows: the non-linear relationship between dose and serotonin transporter (SERT) occupancy. The curve is flat at high doses — most transporters are already blocked, so a dose cut has little biological impact — and much steeper at low doses, where even a 1–2 mg reduction causes a disproportionately large drop in occupancy. Your taper steps are spaced along this curve so each step removes a similar amount of occupancy.
Hill curve of modelled receptor occupancy versus dose. Current dose near 60.0 milligrams per day.
Modelled Hill-curve occupancy — illustrative only. PET-derived parameters vary by study; your prescriber may use different clinical targets. Small mg changes near zero can still produce large occupancy shifts.
Want a full taper protocol?
This page shows a quick schedule for this drug. For the guided path — pre-taper risk quiz, formulation-aware steps, and email delivery — continue in the builder.
How to Taper Off Cymbalta (Duloxetine) Safely
How to taper off Cymbalta (duloxetine) safely means planning for a short half-life — about 12 hours — and capsules that cannot be split. Coming off duloxetine is often harder than the milligram numbers suggest. A hyperbolic reduction with bead counting or a compounded liquid is the usual path, agreed with your prescriber.
Duloxetine is an SNRI used for depression, anxiety, and some pain indications. Withdrawal can arrive quickly after a large cut. The calculator on this page drafts an example schedule to take to that appointment — it is not a dose instruction.
About this guide
This is general information about duloxetine for people taking it, thinking about starting or stopping. It is not personal medical advice, and it does not tell you what dose to take or how to change one. Those decisions belong with the prescriber who knows your history.
If anything here differs from what your own doctor or pharmacist has told you, go with them.
How long people usually take it
Duloxetine is not usually a short course. NICE advises that people starting an antidepressant should be told treatment may need to continue for at least six months after symptoms have settled, with regular review. For people who have had several episodes, or who are at higher risk of becoming unwell again, it is often considerably longer. If you are taking it for pain rather than depression, how long to stay on is still a review with your prescriber, not a decision to make from a webpage.
This matters if you are thinking about stopping, because stopping early carries a real risk. In a UK trial in general practice, among people who had been well enough that stopping seemed reasonable, 56% of those who stopped became unwell again within a year, compared with 39% of those who continued. That is not an argument for staying on antidepressants indefinitely, and many people come off them successfully and stay well. It is an argument for the timing being a decision you make deliberately with your prescriber, rather than one you make on the day you run out.
What people commonly notice while taking it
People commonly notice nausea, dry mouth, sleep change, sweating, dizziness, and constipation. Sexual side effects occur with SNRIs as they do with SSRIs, and are worth raising because they often go unmentioned.
Duloxetine can raise blood pressure and affect liver tests. Tell your prescriber if you have liver disease, drink heavily, or take other medicines that stress the liver. Early effects often settle over a few weeks; some do not.
Thinking about stopping
There are many different reasons for people to think about stopping. This can be that they have been well for a long time, the side effects have come to outweigh the benefit, they are planning a pregnancy, or circumstances have changed.
What helps is having the conversation before the plan rather than after it. Some questions that are worth taking to the appointment:
- how long you have been taking it, and how long it has been since you last felt unwell
- whether anything in the next few months makes this a difficult time to start
- what happened if you have tried before, and what you would do differently
- how the two of you will tell withdrawal symptoms from the original problem returning
- who you contact, and how quickly, if it becomes difficult
One thing is worth being clear about: duloxetine should not be stopped abruptly. NICE advises against stopping antidepressants suddenly except in rare and serious circumstances, such as a severe reaction to the medicine.
What coming off Cymbalta actually feels like, week by week
With a half-life of about 12 hours, an oversized reduction often declares itself within a day or two: dizziness, brain zaps, nausea, irritability, insomnia, and a flu-like malaise are commonly described. Some people also notice a rebound of pain if duloxetine was helping neuropathic or musculoskeletal symptoms.
Missed doses feel punishing with this drug — timing matters as much as the size of the cut.
How common is this? The research does not give a clean answer, and it is worth being straight about that. A large review published in 2024 found that about a third of people had at least one symptom after stopping an antidepressant, but also that about one in six had symptoms after stopping a dummy tablet, leaving roughly one in six or seven that could be attributed to the medicine itself. A reanalysis published in 2025, which looked only at the studies that asked people systematically rather than waiting for them to volunteer symptoms, arrived at around half.
Almost all of that research involves people who had taken antidepressants for a few months. Very little of it describes what happens after several years, which is the situation many people reading this are actually in.
The practical reading: common enough to plan for, not so certain that you should expect it.
Withdrawal or relapse — how to tell them apart
Withdrawal symptoms tend to begin within a day or two of a change, are often dominated by physical and sensory symptoms, and settle relatively quickly if the previous dose is restored.
A return of depression or anxiety tends to build over weeks, resembles how your original illness felt rather than a physical upset, and does not lift within a day or two if the dose goes back up.
That distinction is useful, but it is not perfect and it should not be used as a test you apply alone. NICE's guidance on withdrawal makes the point directly that withdrawal symptoms can be delayed, can be prolonged, and can affect mental health as well as physical health. If you cannot tell which you are dealing with, that is a normal position to be in and a good reason to speak to your prescriber.
Why the last part is often the hardest
This catches people out, and it is worth understanding, because it is the most common reason a reduction that had been going well stops going well.
The relationship between the dose and the effect at the nerve cell is not a straight line. At higher doses the effect is close to its ceiling, so removing some milligrams changes relatively little. At low doses, removing the same number of milligrams makes a much bigger difference.
In practical terms, a reduction that you barely noticed near the top can feel like a much larger change near the bottom, even though the arithmetic looks identical. This is why NICE recommends reductions that are proportionate to the dose you are currently taking, so that the steps become smaller as the dose comes down, and it is why the final stretch often takes longer than everything before it.
It is a feature of how the medicine works. It is not a sign that something has gone wrong, and it is not a sign that you are doing it badly.
The practical part of this is that enteric-coated capsules are not designed to be opened or split. So at exactly the point where the steps need to get smaller, listed strengths stop being able to make them smaller. That is a formulation problem — bead counting or a compounded liquid — not a test of determination.
Cymbalta taper schedules by starting dose (60, 30, 20 mg)
Whatever your starting point, the safer pattern is a hyperbolic taper — equal occupancy steps, not equal milligram steps. The table above is an example of that pattern, not a prescription. Take it to your prescriber.
Capsules commonly come in 20 mg, 30 mg, and 60 mg. Jumping from one listed strength to the next is a linear cut and often a larger occupancy drop than it looks. Intermediate doses usually need bead counting between capsule strengths.
From the lowest common capsule, listed strengths run out. Finishing often needs bead counting or a compounded liquid. That is a conversation about formulations, not a sequence to run at home.
If it gets worse: pausing and reinstatement
If a reduction is harder than you expected, speak to your prescriber rather than invent the next step from a webpage. Duloxetine leaves the body quickly, so both trouble and relief after going back up can appear within a day. They can help you tell withdrawal from the original problem returning — including pain — and decide whether the plan needs more time or a different form.
This is educational information. Do not change your dose without your prescriber's input.
Bead counting and small doses of duloxetine
Duloxetine is supplied as enteric-coated bead capsules. Capsules must not be split, crushed, or chewed, or the coating is lost. The smallest routine strength is often 20 mg a day.
For doses between listed strengths, some people — with pharmacist guidance — open a capsule and count beads to approximate a target amount, keeping unused beads dry. A compounded liquid can be easier for the final stretch. Whether that applies to you is a question for your prescriber and pharmacist.
A note on what your leaflet says
The patient information leaflet in the box often says that when stopping, the dose should be reduced over a period of at least one to two weeks. NICE's guidance on withdrawal describes a slower, stepwise reduction that gets gentler as the dose falls, and says the process can take several months or more.
If your leaflet and your prescriber appear to disagree, this is usually why. Neither is making a mistake. The leaflet states a minimum; the guideline describes what many people actually need.
When to get help quickly
Contact your prescriber promptly if:
- your mood drops significantly, or you feel worse than you did before you started
- you have thoughts of harming yourself or ending your life. If you are in immediate danger, call emergency services — 911 in the US, or your local emergency number
- symptoms after a dose change are getting worse rather than settling, or you cannot manage them
- you become confused or unsteady, or feel physically unwell in a way that is new
- you develop agitation with shivering, twitching, a racing heart or a fever
- you become pregnant, or are planning to
Stopping duloxetine suddenly is not the answer to any of the above. Speak to someone first. Crisis lines for your region are listed at the bottom of this page.
The bottom line
Coming off duloxetine is doable when the plan accounts for fast withdrawal and capsules that will not split. Use the planning table as something to take to your prescriber, and ask early how the small steps will actually be made.
Bead-counting estimator (Cymbalta / duloxetine)
Open a capsule and remove a measured portion of beads to approximate a fractional dose. Use this only with prescriber and pharmacist guidance — bead counts vary by lot.
Target next dose: 54 mg (≈ 468 beads from a 30 mg capsule; discard ≈ 0 beads).
The target dose exceeds the chosen capsule's content. Choose a larger capsule or a smaller reduction.
Beads per mg ≈ 8.67. Bead counts can vary 10–20% by lot — confirm with your pharmacist and only count once per dose.
Method described in the Maudsley Deprescribing Guidelines (2024). Compounded liquid is the more accurate option where available.
Milligram scale guidance (advanced — prescriber/pharmacist approval required)
When a dose is below what you can split from a licensed tablet, some people weigh crushed tablet powder. This is not exact chemistry — it is a last resort. Liquid or compounded formulations are safer when available.
- Resolution: at least 0.001 g (1 mg) — not a kitchen scale.
- Include a calibration weight and use a draft shield if possible.
- Weigh on a stable surface; tare your container first.
- Crushed tablet weight ≠ exact active ingredient — drug may not be evenly distributed; prefer liquid or compounded specials when available.
- Never split enteric-coated (EC) or extended-release (XR) products — discuss with your pharmacist.
Example searches (confirm specs before buying):
Key facts about hyperbolic antidepressant tapering
The calculator algorithm is based on peer-reviewed research and has been reviewed by our medical advisors to ensure the accuracy of the tapering model.
72%
discontinued their antidepressant using hyperbolic tapering strips in a real-world study
71% of the same people had previously tried to stop at least once and been unsuccessful; the study did not record which method those earlier attempts used. Figures come from tapering-strip research and may not generalise to every taper.
Source: Groot et al., Therapeutic Advances in Psychopharmacology 2021
56 days
median taper length in that tapering-strip study — not a target; many people taper over 6–12 months or longer
This median reflects tapering-strip use in one study. Your timeline depends on how long you have taken the medication, your withdrawal symptoms, and previous attempts — slower is often safer.
Source: Groot et al., Therapeutic Advances in Psychopharmacology 2021
10%
serotonin transporter occupancy per tapering step
This linear reduction prevents withdrawal. Slower, more gradual tapering over several months has shown greater success in reducing withdrawal symptoms than short tapers.
Claro — tapering companion
A protocol isn’t enough — you need support.
Tapering can take months, sometimes years. Claro helps you track each step, log symptoms, and spot when a reduction was too fast — with psychiatrist-reviewed guidance. Join early access while we launch the app.
Related taper guides
Other medications with similar pharmacology or a higher population withdrawal-risk profile. Each guide links to a pre-filled hyperbolic schedule for that drug.
Other SNRI guides
Higher withdrawal risk
Frequently asked questions about duloxetine
Common questions about how to taper off duloxetine, hyperbolic schedules, and withdrawal — written for people who want to come off antidepressants safely with their prescriber.
How do you taper off Cymbalta (duloxetine)?
How do bead-counting tapers work for Cymbalta?
How long does Cymbalta withdrawal last?
Can you stop Cymbalta cold turkey?
Do you have to taper off Cymbalta?
Why is Cymbalta withdrawal so hard?
What is an antidepressant tapering calculator?
Why use a tapering calculator?
How does an antidepressant taper calculator work?
What is hyperbolic tapering and why is it recommended?
What is the safest way to taper off antidepressants?
How slowly should antidepressants be reduced?
What are common antidepressant withdrawal symptoms?
What is the difference between antidepressant withdrawal and relapse?
Is it dangerous to stop antidepressants cold turkey?
Why are the last antidepressant dose reductions often the hardest?
Which antidepressants are hardest to taper off?
Need a different dose or speed?
Use the guided builder to enter your current dose, region, and taper preset — then email a draft you can review with your prescriber.
Request custom protocol →Clinical references
- [1]Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry 2019.doi:10.1016/S2215-0366(19)30032-XProposes hyperbolic dose reduction based on receptor-occupancy curves; the methodological basis of every modern taper calculator.
- [2]Horowitz MA, Taylor D. The Maudsley Deprescribing Guidelines. Wiley 2024.doi:10.1002/9781394291052Per-drug operational manual for hyperbolic tapering across SSRIs, SNRIs, benzodiazepines, gabapentinoids, and antipsychotics.
- [3]Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects. Addictive Behaviors 2019.doi:10.1016/j.addbeh.2018.08.027Systematic review: 56% of people who discontinue antidepressants experience withdrawal effects; 46% rate them as severe.
- [4]Henssler J et al. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. The Lancet Psychiatry 2024.doi:10.1016/S2215-0366(24)00133-0Meta-analysis of 79 studies (≈21,000 patients): pooled incidence of discontinuation symptoms ~31%; severe symptoms ~2.8%.
- [5]Groot PC, van Os J. Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study. Therapeutic Advances in Psychopharmacology 2021.doi:10.1177/2045125321103932772% of patients successfully discontinued antidepressants after switching to the hyperbolic model; 71% had previously failed to come off without tapering strips.
- [6]Groot PC, van Os J. Antidepressant tapering strips to help people come off medication: real-world outcomes. Therapeutic Advances in Psychopharmacology 2023.doi:10.1177/20451253231171518Of 1,194 patients using hyperbolic taper strips after previous failed attempts, ~71% successfully discontinued their antidepressant.
- [7]Framer A. What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications. Therapeutic Advances in Psychopharmacology 2021.doi:10.1177/2045125321991274Describes the "windows and waves" pattern of withdrawal recovery and supports patient-led pacing.
- [8]Hengartner MP et al. Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives. Therapeutic Advances in Psychopharmacology 2020.doi:10.1177/2045125320967183Descriptive analysis of 69 protracted withdrawal cases: median duration 79 weeks; 47% report suicidality during withdrawal.
- [9]Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychotherapy and Psychosomatics 2020.doi:10.1159/000506868Taxonomy distinguishing new withdrawal symptoms, rebound, and persistent post-withdrawal disorder; the standard framework for withdrawal vs. relapse.
- [10]Kalfas M et al. Incidence and Nature of Antidepressant Discontinuation Symptoms. JAMA Psychiatry 2025.doi:10.1001/jamapsychiatry.2025.1362Recent meta-analysis: dizziness was the most common discontinuation symptom in the first 2 weeks after stopping antidepressants, followed by nausea, vertigo, and nervousness.
- [11]Gabriel M, Sharma V. Antidepressant discontinuation syndrome. Canadian Medical Association Journal 2017.doi:10.1503/cmaj.160991Clinical review of antidepressant discontinuation syndrome: onset within days of dose reduction, typical symptom course, and management.
- [12]Papp A, Onton J. Brain Zaps: An Underappreciated Symptom of Antidepressant Discontinuation. The Primary Care Companion for CNS Disorders 2018.doi:10.4088/pcc.18m02311Characterises "brain zaps" — brief electric-shock sensations — as a common antidepressant discontinuation symptom.
- [13]Wang J, Cosci F. Acute and persistent withdrawal syndromes following discontinuation of antidepressants in children and adolescents: a systematic review. Therapeutic Advances in Psychopharmacology 2025.doi:10.1177/20451253251404780Systematic review of acute and persistent antidepressant withdrawal syndromes; reinforces reducing only when stable and under supervision.
- [14]Horowitz M, Taylor D. Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies. BJPsych Advances 2022.doi:10.1192/bja.2021.62Frames how clinicians can distinguish antidepressant withdrawal from relapse of the underlying condition.
- [15]Sørensen A, Ruhé HG, Munkholm K. The relationship between dose and serotonin transporter occupancy of antidepressants — a systematic review. Molecular Psychiatry 2021.doi:10.1038/s41380-021-01285-wSystematic review of dose–SERT-occupancy relationships across antidepressants; confirms the hyperbolic curve underlying proportional tapering.
- [16]Reeve R, Turner JR. Pharmacodynamic models: parameterizing the Hill equation, Michaelis-Menten, the logistic curve, and relationships among these models. Journal of Biopharmaceutical Statistics 2013.doi:10.1080/10543406.2012.756496Explains how the Hill equation, Michaelis-Menten, and logistic models relate — the mathematical basis for the occupancy curve used here.
- [17]Preskorn SH. The use of biomarkers in psychiatric research: how serotonin transporter occupancy explains the dose-response curves of SSRIs. Journal of Psychiatric Practice 2012.LinkShows how SERT occupancy explains the non-linear dose–response curves of SSRIs.
- [18]Cohrs D, Shapiro B. The relationship between SERT occupancy and extracellular serotonin concentration is hyperbolic, not linear: implications for safely tapering SRI antidepressants. SSRN (preprint) 2026.doi:10.2139/ssrn.6176553Argues the SERT-occupancy to serotonin relationship is itself hyperbolic, reinforcing proportional (hyperbolic) tapering.
- [19]Moncrieff J et al. Evidence on antidepressant withdrawal: an appraisal and reanalysis of a recent systematic review. Psychological Medicine 2025.doi:10.1017/S0033291725100652Reappraisal of recent withdrawal-incidence evidence; relevant to how withdrawal rates are interpreted.
- [20]Wilson E, Lader M. A review of the management of antidepressant discontinuation symptoms. Therapeutic Advances in Psychopharmacology 2015.doi:10.1177/2045125315612334Practical review of how to manage antidepressant discontinuation symptoms, including tapering and reinstatement.
- [21]Groot PC, van Os J. Outcome of antidepressant drug discontinuation with tapering strips after 1–5 years. Therapeutic Advances in Psychopharmacology 2020.doi:10.1177/2045125320954609Long-term follow-up (1–5 years) of patients who discontinued antidepressants using hyperbolic taper strips.
- [22]Gury C, Cousin F. Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability. L'Encéphale 1999.LinkHalf-life data for SSRIs — explains why short-half-life drugs (paroxetine, venlafaxine) provoke faster withdrawal.
- [23]Mayo Clinic. Antidepressant withdrawal: Is there such a thing?. Mayo Clinic — Expert Answers 2024.LinkPatient-facing explainer on antidepressant discontinuation symptoms and gradual tapering.
- [24]NHS Scotland — Right Decision Service. Antidepressants — quality prescribing: difficulty withdrawing from an SSRI/SNRI. NHS Scotland 2024.LinkNHS Scotland guidance on recognising and managing difficulty withdrawing from SSRIs/SNRIs.
- [25]The Carlat Psychiatry Report. Clinical pearls for hyperbolic tapering of psychiatric medications in older adults. The Carlat Report 2024.LinkPractical clinical pearls for applying hyperbolic tapering, including in older adults.
- [26]Royal College of Psychiatrists. Stopping antidepressants — information for patients and carers. Royal College of Psychiatrists 2024.LinkRCPsych patient-facing guidance on coming off antidepressants safely.
- [27]National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management. NICE guideline [NG222]. NICE 2022.LinkUK national guideline endorsing proportional (hyperbolic) tapering and the use of liquid formulations to enable small final doses.
- [28]National Institute for Health and Care Excellence (NICE). Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults. NICE guideline [NG215]. NICE 2022.LinkUK national guideline on withdrawal: symptoms can be delayed or prolonged, and reductions should get gentler as the dose falls.
- [29]Lewis G et al. Maintenance or Discontinuation of Antidepressants in Primary Care. New England Journal of Medicine 2021.doi:10.1056/NEJMoa2106356Among people well enough that stopping seemed reasonable, 56% who stopped became unwell again within a year versus 39% who continued.
- [30]Royal College of Psychiatrists. Stopping antidepressants — position statement (CR225). Royal College of Psychiatrists 2020.LinkRCPsych acknowledges withdrawal can be severe and long-lasting; recommends slow, individualised tapers.
- [31]NHG et al. Multidisciplinary document: Discontinuation of SSRIs and SNRIs (2018; revised 2023). Multidisciplinary Document (Netherlands) 2018.LinkFirst national guideline to explicitly endorse hyperbolic tapering and the use of taper strips (compounded by Regenboog Apotheek).
- [32]Medicines and Healthcare products Regulatory Agency (MHRA). Summary of Product Characteristics — SSRI and SNRI products (UK). electronic Medicines Compendium (emc) 2023.LinkAuthoritative UK formulary data (tablet strengths, oral solutions) used to validate the UK region in the calculator.
- [33]U.S. Food and Drug Administration. Prescribing information (Structured Product Labeling) for SSRI/SNRI products. FDA / DailyMed 2024.LinkAuthoritative US formulary data (tablet strengths, oral solutions/concentrates) used to validate the US region in the calculator.
- [34]Health Canada. Health Canada — Drug Product Database. Health Canada 2024.LinkAuthoritative Canadian formulary data used to validate the Canada region in the calculator.
- [35]Therapeutic Goods Administration (TGA). Therapeutic Goods Administration — Australian Register of Therapeutic Goods (ARTG). TGA / ARTG 2024.LinkAuthoritative Australian formulary data used to validate the Australia region in the calculator.
- [36]College ter Beoordeling van Geneesmiddelen (CBG-MEB). CBG-MEB — Medicines Information Bank (Netherlands). CBG-MEB 2024.LinkAuthoritative Dutch formulary data; cross-checked with Regenboog Apotheek taper-strip availability.
- [37]Regenboog Apotheek, Cinetto. Taperingstrip.com — Regenboog Apotheek. Patient resource (NL) 2024.LinkPioneer of standardised taper strips referenced in the Dutch national guideline.
If you are in crisis or having thoughts of suicide, do not wait for an email response. Find a crisis helpline near you immediately →